NOS2 knockdown by RNA interference strategy or by specific inhibitors negatively affected the proliferation and invasiveness of GBM cells [20,25], and was able to reduce the progression of subcutaneous and intracranial human glioma xenografts in mice [24]. The gene discussed is NOS2; the disease is central nervous system cancer.